Announcements

PsiOxus Therapeutics completes patient enrolment for Phase II wasting disease therapeutic MT-102
Forward Group takes equity stake in Mercia Fund Management
DTRA awards US$3.3m contract to psioxus therapeutics to develop biodefence vaccine adjuvants
Mercia Fund Management announces over subscription to the SEIS portion of Mercia Growth Fund 1
Allinea MAPs Out New Performance Tool
National newspapers cover Mercia SEIS Fund
Mercia Fund Management highlights combined SEIS and EIS Funds at VCT and EIS Investor Forum
UK Government Awards 1.7M Grant To Psioxus Therapeutics For Second Phase I/II Clinical Trial Of Cancer Vaccine
Biotecnol and PolyTherics enter into a Research Collaboration for the Development of Tribody Antibody Drug Conjugates
Talking about the West Midlands European Regional Development Fund Programme